SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

OpenAI admits its AI agents used a wiki as a springboard for rogue behavior

Anthropic pushes back IPO as investors await one of AI’s biggest public-market tests

The biggest opportunity is not in AI infrastructure. It's in applications.

More AI agents can mean more work for humans

Buzz

Most popular

Daily

Weekly

1

Palo Alto’s CEO invested in the startup his company just bought for $500 million

2

ServiceNow acquires Israeli AI startup Sweep in deal estimated at hundreds of millions

3

Upwind raises $300 million, more than doubles valuation to $3.8 billion in five months

4

The 50 most promising Israeli startups - 2026

5

Proofpoint in talks to acquire Israeli cybersecurity company Varonis

Actavis

5 stories about Actavis

חברת תרופות אלרגן

Allergan Says Teva Bears Sole Liability for Actavis' Actions

02.09.19|Hezi Sternlicht

Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012

אינפו טבע מחירי תרופות גנריות Teva generic drug prices

The Crucial Piece of Information Teva Overlooked

24.12.17|Sophie Shulman

When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.

אורי טל טנא פרשן שוק ההון

Teva Wants to Be Like Mylan: Agile, Lean and Profitable

17.12.17|Uri Tal-Tenne

The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan

Allergan Sketches Road Show to Sell Teva Stake

14.08.17|Golan Hazani

The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter

Allergan Can Now Sell 9.8% Teva Stake

03.08.17|Dror Reich

Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended